Friday, October 16, 2020 1:43:55 PM
RLF raised $30M+ from the 400M shares to GEM recently, to continue Trials and start operations after the 'partnership' with NRX. It's only $400k for the VIP (their price obviously less) drugs and then administering it.
Nel, there are Plenty of patients now to complete enrollments. They deserve treatments. Cant figure why you say April for data/Trial completion except that they aren't enrolling anymore.?. Also cant figure why they're stopping at 102 in the phase 2b of the 2b/3 IV Trial. Sure great data, BUT. Look at the FIELD of companies going thru the process and the MANY different approaches being tested and their value Proven or Not, ALL thru full normal Clinical Trials' progression.
I dont count on inside help (Harris?) at the FDA, especially whit the current state of political confusions they are dealind with. All JMHO.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM